Last 12 months
Inside the activity.
0 purchase rows · 116 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 6 |
| Jan 2026 | 0 | 5 |
| Feb 2026 | 0 | 17 |
| Mar 2026 | 0 | 1 |
| Apr 2026 | 0 | 23 |
| May 2026 | 0 | 15 |
| Jun 2026 | 0 | 2 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 5 |
| Sep 2026 | 0 | 41 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 09, 2019 Filed May 11, 2019 01:40 UTC |
Clague LauraChief Financial Officer
|
GrantEmployee stock option (right to buy) · Derivative | 40,000 | $0.00 Strike: $17.96 | $0.00 |
DisclosureSEC source: 0001209191-19-029174 · doc4.xml · derivative · entry 2 Clague Laura · CIK 0001388773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2029-05-08 F1 · derivative.exercise_date: One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| May 09, 2019 Filed May 11, 2019 01:40 UTC |
Clague LauraChief Financial Officer
|
GrantCommon Stock | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-029174 · doc4.xml · nonDerivative · entry 1 Clague Laura · CIK 0001388773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Read SEC document |
| May 09, 2019 Filed May 11, 2019 01:42 UTC |
REED ELIZABETH ESVP, GC & Corporate Secretary
|
GrantPerformance-based restricted stock units · Derivative | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-029177 · doc4.xml · derivative · entry 3 REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer. F3 · derivative.exercise_date: This grant will vest upon the later of (i) 12 months from the date of grant, and (ii) the achievement of specified clinical and regulatory milestones, provided that the grant will expire on May 9, 2023 to the extent the specified clinical and regulatory milestones are not achieved by such date. F3 · derivative.expiration_date: This grant will vest upon the later of (i) 12 months from the date of grant, and (ii) the achievement of specified clinical and regulatory milestones, provided that the grant will expire on May 9, 2023 to the extent the specified clinical and regulatory milestones are not achieved by such date. Read SEC document |
| May 09, 2019 Filed May 11, 2019 01:42 UTC |
REED ELIZABETH ESVP, GC & Corporate Secretary
|
GrantEmployee stock option (right to buy) · Derivative | 40,000 | $0.00 Strike: $17.96 | $0.00 |
DisclosureSEC source: 0001209191-19-029177 · doc4.xml · derivative · entry 2 REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2029-05-08 F1 · derivative.exercise_date: One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| May 09, 2019 Filed May 11, 2019 01:42 UTC |
REED ELIZABETH ESVP, GC & Corporate Secretary
|
GrantCommon Stock | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-029177 · doc4.xml · nonDerivative · entry 1 REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,558 Read SEC document |
| May 09, 2019 Filed May 11, 2019 01:41 UTC |
ROTE WILLIAM E.Senior Vice President, R&D
|
GrantPerformance-based restricted stock units · Derivative | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-029176 · doc4.xml · derivative · entry 3 ROTE WILLIAM E. · CIK 0001698262 · Senior Vice President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer. F3 · derivative.exercise_date: This grant will vest upon the later of (i) 12 months from the date of grant, and (ii) the achievement of specified clinical and regulatory milestones, provided that the grant will expire on May 9, 2023 to the extent the specified clinical and regulatory milestones are not achieved by such date. F3 · derivative.expiration_date: This grant will vest upon the later of (i) 12 months from the date of grant, and (ii) the achievement of specified clinical and regulatory milestones, provided that the grant will expire on May 9, 2023 to the extent the specified clinical and regulatory milestones are not achieved by such date. Read SEC document |
| May 09, 2019 Filed May 11, 2019 01:41 UTC |
ROTE WILLIAM E.Senior Vice President, R&D
|
GrantEmployee stock option (right to buy) · Derivative | 40,000 | $0.00 Strike: $17.96 | $0.00 |
DisclosureSEC source: 0001209191-19-029176 · doc4.xml · derivative · entry 2 ROTE WILLIAM E. · CIK 0001698262 · Senior Vice President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2029-05-08 F1 · derivative.exercise_date: One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| May 09, 2019 Filed May 11, 2019 01:41 UTC |
ROTE WILLIAM E.Senior Vice President, R&D
|
GrantCommon Stock | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-029176 · doc4.xml · nonDerivative · entry 1 ROTE WILLIAM E. · CIK 0001698262 · Senior Vice President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,810 Read SEC document |
| May 09, 2019 Filed May 11, 2019 01:41 UTC |
Rosenberg Noah L.Chief Medical Officer
|
GrantPerformance-based restricted stock units · Derivative | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-029175 · doc4.xml · derivative · entry 3 Rosenberg Noah L. · CIK 0001579649 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer. F3 · derivative.exercise_date: This grant will vest upon the later of (i) 12 months from the date of grant, and (ii) the achievement of specified clinical and regulatory milestones, provided that the grant will expire on May 9, 2023 to the extent the specified clinical and regulatory milestones are not achieved by such date. F3 · derivative.expiration_date: This grant will vest upon the later of (i) 12 months from the date of grant, and (ii) the achievement of specified clinical and regulatory milestones, provided that the grant will expire on May 9, 2023 to the extent the specified clinical and regulatory milestones are not achieved by such date. Read SEC document |
| May 09, 2019 Filed May 11, 2019 01:41 UTC |
Rosenberg Noah L.Chief Medical Officer
|
GrantEmployee stock option (right to buy) · Derivative | 40,000 | $0.00 Strike: $17.96 | $0.00 |
DisclosureSEC source: 0001209191-19-029175 · doc4.xml · derivative · entry 2 Rosenberg Noah L. · CIK 0001579649 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2029-05-08 F1 · derivative.exercise_date: One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| May 09, 2019 Filed May 11, 2019 01:41 UTC |
Rosenberg Noah L.Chief Medical Officer
|
GrantCommon Stock | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-029175 · doc4.xml · nonDerivative · entry 1 Rosenberg Noah L. · CIK 0001579649 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Read SEC document |
| May 09, 2019 Filed May 11, 2019 01:39 UTC |
Dube Eric MDirector · Chief Executive Officer
|
GrantPerformance-based restricted stock units · Derivative | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-029173 · doc4.xml · derivative · entry 1 Dube Eric M · CIK 0001763494 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer. F2 · derivative.exercise_date: This grant will vest upon the later of (i) 12 months from the date of grant, and (ii) the achievement of specified clinical and regulatory milestones, provided that the grant will expire on May 9, 2023 to the extent the specified clinical and regulatory milestones are not achieved by such date. F2 · derivative.expiration_date: This grant will vest upon the later of (i) 12 months from the date of grant, and (ii) the achievement of specified clinical and regulatory milestones, provided that the grant will expire on May 9, 2023 to the extent the specified clinical and regulatory milestones are not achieved by such date. Read SEC document |
| May 08, 2019 Filed May 11, 2019 00:36 UTC |
LYONS GARY ADirector
|
GrantEmployee stock option (right to buy) · Derivative | 8,000 | $0.00 Strike: $17.94 | $0.00 |
DisclosureSEC source: 0001209191-19-029155 · doc4.xml · derivative · entry 2 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2029-05-07 Read SEC document |
| May 08, 2019 Filed May 11, 2019 00:36 UTC |
LYONS GARY ADirector
|
GrantCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-029155 · doc4.xml · nonDerivative · entry 1 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,000 Read SEC document |
| May 08, 2019 Filed May 11, 2019 00:37 UTC |
Orwin John ADirector
|
GrantEmployee stock option (right to buy) · Derivative | 8,000 | $0.00 Strike: $17.94 | $0.00 |
DisclosureSEC source: 0001209191-19-029157 · doc4.xml · derivative · entry 2 Orwin John A · CIK 0001477384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2029-05-07 Read SEC document |
| May 08, 2019 Filed May 11, 2019 00:37 UTC |
Orwin John ADirector
|
GrantCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-029157 · doc4.xml · nonDerivative · entry 1 Orwin John A · CIK 0001477384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,875 Read SEC document |
| May 08, 2019 Filed May 11, 2019 00:38 UTC |
Squarer RonDirector
|
GrantEmployee stock option (right to buy) · Derivative | 8,000 | $0.00 Strike: $17.94 | $0.00 |
DisclosureSEC source: 0001209191-19-029159 · doc4.xml · derivative · entry 2 Squarer Ron · CIK 0001454001 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2029-05-07 Read SEC document |
| May 08, 2019 Filed May 11, 2019 00:38 UTC |
Squarer RonDirector
|
GrantCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-029159 · doc4.xml · nonDerivative · entry 1 Squarer Ron · CIK 0001454001 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,875 Read SEC document |
| May 08, 2019 Filed May 11, 2019 00:35 UTC |
KOZARICH JOHN WDirector
|
GrantEmployee stock option (right to buy) · Derivative | 8,000 | $0.00 Strike: $17.94 | $0.00 |
DisclosureSEC source: 0001209191-19-029154 · doc4.xml · derivative · entry 2 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2029-05-07 Read SEC document |
| May 08, 2019 Filed May 11, 2019 00:35 UTC |
KOZARICH JOHN WDirector
|
GrantCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-029154 · doc4.xml · nonDerivative · entry 1 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,000 Read SEC document |
| May 08, 2019 Filed May 11, 2019 00:37 UTC |
Meckler Jeffrey ADirector
|
GrantEmployee stock option (right to buy) · Derivative | 8,000 | $0.00 Strike: $17.94 | $0.00 |
DisclosureSEC source: 0001209191-19-029156 · doc4.xml · derivative · entry 2 Meckler Jeffrey A · CIK 0001506916 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2029-05-07 Read SEC document |
| May 08, 2019 Filed May 11, 2019 00:37 UTC |
Meckler Jeffrey ADirector
|
GrantCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-029156 · doc4.xml · nonDerivative · entry 1 Meckler Jeffrey A · CIK 0001506916 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,000 Read SEC document |
| May 08, 2019 Filed May 11, 2019 00:34 UTC |
Coughlin TimothyDirector
|
GrantEmployee stock option (right to buy) · Derivative | 8,000 | $0.00 Strike: $17.94 | $0.00 |
DisclosureSEC source: 0001209191-19-029153 · doc4.xml · derivative · entry 2 Coughlin Timothy P · CIK 0001376043 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2029-05-07 Read SEC document |
| May 08, 2019 Filed May 11, 2019 00:34 UTC |
Coughlin TimothyDirector
|
GrantCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-029153 · doc4.xml · nonDerivative · entry 1 Coughlin Timothy P · CIK 0001376043 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,000 Read SEC document |
| May 08, 2019 Filed May 11, 2019 00:33 UTC |
Baynes Roy D.Director
|
GrantEmployee stock option (right to buy) · Derivative | 8,000 | $0.00 Strike: $17.94 | $0.00 |
DisclosureSEC source: 0001209191-19-029152 · doc4.xml · derivative · entry 2 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2029-05-07 Read SEC document |
| May 08, 2019 Filed May 11, 2019 00:33 UTC |
Baynes Roy D.Director
|
GrantCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-029152 · doc4.xml · nonDerivative · entry 1 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Read SEC document |
| May 08, 2019 Filed May 11, 2019 00:32 UTC |
ASELAGE STEVEDirector
|
GrantEmployee stock option (right to buy) · Derivative | 8,000 | $0.00 Strike: $17.94 | $0.00 |
DisclosureSEC source: 0001209191-19-029151 · doc4.xml · derivative · entry 2 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2029-05-07 Read SEC document |
| May 08, 2019 Filed May 11, 2019 00:32 UTC |
ASELAGE STEVEDirector
|
GrantCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-029151 · doc4.xml · nonDerivative · entry 1 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 259,642 Read SEC document |
| February 19, 2019 Filed Feb 21, 2019 00:58 UTC |
ROTE WILLIAM E.Senior Vice President, R&D
|
SaleCommon Stock | 1,250 | $21.52 | $26,900.00 |
DisclosureSEC source: 0001209191-19-011822 · doc4.xml · nonDerivative · entry 2 ROTE WILLIAM E. · CIK 0001698262 · Senior Vice President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,810 F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document |
| February 15, 2019 Filed Feb 21, 2019 00:58 UTC |
ROTE WILLIAM E.Senior Vice President, R&D
|
SaleCommon Stock | 1,250 | $21.44 | $26,800.00 |
DisclosureSEC source: 0001209191-19-011822 · doc4.xml · nonDerivative · entry 1 ROTE WILLIAM E. · CIK 0001698262 · Senior Vice President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,060 F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units. F2 · balance_after: Includes 303 shares of the Issuer acquired by the reporting person on November 30, 2018 pursuant to an employee stock purchase program. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 01:50 UTC |
REED ELIZABETH ESVP, GC & Corporate Secretary
|
SaleCommon Stock | 884 | $21.50 | $19,006.00 |
DisclosureSEC source: 0001209191-19-009927 · doc4.xml · nonDerivative · entry 2 REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,558 F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 01:49 UTC |
ROTE WILLIAM E.Senior Vice President, R&D
|
SaleCommon Stock | 992 | $21.50 | $21,328.00 |
DisclosureSEC source: 0001209191-19-009926 · doc4.xml · nonDerivative · entry 2 ROTE WILLIAM E. · CIK 0001698262 · Senior Vice President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,007 F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 01:49 UTC |
Clague LauraChief Financial Officer
|
SaleCommon Stock | 1,016 | $21.50 | $21,844.00 |
DisclosureSEC source: 0001209191-19-009925 · doc4.xml · nonDerivative · entry 2 Clague Laura · CIK 0001388773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 01:47 UTC |
ASELAGE STEVEDirector · Chief Executive Officer
|
SaleCommon Stock | 1,065 | $21.50 | $22,897.50 |
DisclosureSEC source: 0001209191-19-009924 · doc4.xml · nonDerivative · entry 2 ASELAGE STEVE · CIK 0001221599 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 257,642 F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document |
| February 11, 2019 Filed Feb 14, 2019 01:50 UTC |
REED ELIZABETH ESVP, GC & Corporate Secretary
|
SaleCommon Stock | 885 | $21.38 | $18,921.30 |
DisclosureSEC source: 0001209191-19-009927 · doc4.xml · nonDerivative · entry 1 REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,442 F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document |
| February 11, 2019 Filed Feb 14, 2019 01:49 UTC |
ROTE WILLIAM E.Senior Vice President, R&D
|
SaleCommon Stock | 993 | $21.38 | $21,230.34 |
DisclosureSEC source: 0001209191-19-009926 · doc4.xml · nonDerivative · entry 1 ROTE WILLIAM E. · CIK 0001698262 · Senior Vice President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,999 F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document |
| February 11, 2019 Filed Feb 14, 2019 01:49 UTC |
Clague LauraChief Financial Officer
|
SaleCommon Stock | 1,017 | $21.38 | $21,743.46 |
DisclosureSEC source: 0001209191-19-009925 · doc4.xml · nonDerivative · entry 1 Clague Laura · CIK 0001388773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,016 F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document |
| February 11, 2019 Filed Feb 14, 2019 01:47 UTC |
ASELAGE STEVEDirector · Chief Executive Officer
|
SaleCommon Stock | 1,065 | $21.38 | $22,769.70 |
DisclosureSEC source: 0001209191-19-009924 · doc4.xml · nonDerivative · entry 1 ASELAGE STEVE · CIK 0001221599 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 258,707 F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document |
| January 09, 2019 Filed Jan 10, 2019 00:43 UTC |
REED ELIZABETH ESVP, GC & Corporate Secretary
|
SaleCommon Stock | 750 | $23.82 | $17,865.00 |
DisclosureSEC source: 0001209191-19-003163 · doc4.xml · nonDerivative · entry 2 REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,327 F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document |
| January 08, 2019 Filed Jan 10, 2019 00:43 UTC |
REED ELIZABETH ESVP, GC & Corporate Secretary
|
SaleCommon Stock | 750 | $24.09 | $18,067.50 |
DisclosureSEC source: 0001209191-19-003163 · doc4.xml · nonDerivative · entry 1 REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,077 F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document |
| January 04, 2019 Filed Jan 8, 2019 22:25 UTC |
Dube Eric MDirector · Chief Executive Officer
|
GrantPerformance-based restricted stock units · Derivative | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-002858 · doc4.xml · derivative · entry 3 Dube Eric M · CIK 0001763494 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer. F3 · derivative.exercise_date: This grant will vest upon the later of (i) 12 months from the date of grant, and (ii) the achievement of specified clinical and regulatory development milestones, provided that the grant will expire on May 9, 2023 to the extent the specified clinical and regulatory milestones are not achieved by such date. F3 · derivative.expiration_date: This grant will vest upon the later of (i) 12 months from the date of grant, and (ii) the achievement of specified clinical and regulatory development milestones, provided that the grant will expire on May 9, 2023 to the extent the specified clinical and regulatory milestones are not achieved by such date. Read SEC document |
| January 04, 2019 Filed Jan 8, 2019 22:25 UTC |
Dube Eric MDirector · Chief Executive Officer
|
GrantEmployee stock option (right to buy) · Derivative | 400,000 | $0.00 Strike: $23.34 | $0.00 |
DisclosureSEC source: 0001209191-19-002858 · doc4.xml · derivative · entry 2 Dube Eric M · CIK 0001763494 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2029-01-03 F1 · derivative.exercise_date: One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| January 04, 2019 Filed Jan 8, 2019 22:25 UTC |
Dube Eric MDirector · Chief Executive Officer
|
GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-002858 · doc4.xml · nonDerivative · entry 1 Dube Eric M · CIK 0001763494 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Read SEC document |
| December 21, 2018 Filed Dec 22, 2018 01:19 UTC |
Clague LauraChief Financial Officer
|
SaleCommon Stock | 900 | $22.34 | $20,108.97 |
DisclosureSEC source: 0001209191-18-064021 · doc4.xml · nonDerivative · entry 3 Clague Laura · CIK 0001388773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,033 F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.285 to $22.55, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| December 21, 2018 Filed Dec 22, 2018 01:19 UTC |
Clague LauraChief Financial Officer
|
SaleCommon Stock | 2,850 | $21.67 | $61,751.24 |
DisclosureSEC source: 0001209191-18-064021 · doc4.xml · nonDerivative · entry 2 Clague Laura · CIK 0001388773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,933 F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.25 to $22.17, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| December 21, 2018 Filed Dec 22, 2018 01:20 UTC |
ASELAGE STEVEDirector · Chief Executive Officer
|
SaleCommon Stock | 900 | $22.35 | $20,111.04 |
DisclosureSEC source: 0001209191-18-064022 · doc4.xml · nonDerivative · entry 3 ASELAGE STEVE · CIK 0001221599 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 259,772 F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.2850 to $22.55, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| December 21, 2018 Filed Dec 22, 2018 01:20 UTC |
ASELAGE STEVEDirector · Chief Executive Officer
|
SaleCommon Stock | 5,288 | $21.69 | $114,718.40 |
DisclosureSEC source: 0001209191-18-064022 · doc4.xml · nonDerivative · entry 2 ASELAGE STEVE · CIK 0001221599 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,672 F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.22 to $22.1975, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| December 20, 2018 Filed Dec 22, 2018 01:19 UTC |
Clague LauraChief Financial Officer
|
SaleCommon Stock | 3,750 | $22.08 | $82,804.50 |
DisclosureSEC source: 0001209191-18-064021 · doc4.xml · nonDerivative · entry 1 Clague Laura · CIK 0001388773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,783 F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.78 to $22.51, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| December 20, 2018 Filed Dec 22, 2018 01:21 UTC |
McFarlane Neil F.Chief Operating Officer
|
SaleCommon Stock | 6,404 | $22.56 | $144,451.83 |
DisclosureSEC source: 0001209191-18-064023 · doc4.xml · nonDerivative · entry 2 McFarlane Neil F. · CIK 0001681098 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,956 F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.24 to $23.02, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| December 20, 2018 Filed Dec 22, 2018 01:21 UTC |
McFarlane Neil F.Chief Operating Officer
|
SaleCommon Stock | 4,721 | $22.00 | $103,881.36 |
DisclosureSEC source: 0001209191-18-064023 · doc4.xml · nonDerivative · entry 1 McFarlane Neil F. · CIK 0001681098 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,360 F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.76 to $22.23, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.